# corporate%20governance
Latest news and articles about corporate%20governance
Total: 75 articles found
Major Shareholder to Pocket ¥200m as Smart‑home Pioneer Faces Profit Slump and R&D Cuts
Haotaitai’s major shareholder plans to sell about 12.07 million shares, potentially raising ~¥200m and bringing total insider proceeds to ~¥274m after earlier disposals. The sale coincides with falling annual profits, shrinking R&D spending and consumer complaints about product quality and after‑sales service, undermining investor confidence in the smart‑home appliance maker.
A Retailer’s Gamble: How Yu Donglai Turned Nearly ¥4bn of Wealth into Employee Ownership
Yu Donglai has converted about ¥3.8–4.0 billion of Pang Donglai’s assets into company equity for all employees, creating a system of shared ownership, profit‑sharing and a new governance committee. The plan emphasizes stability and employee welfare over an IPO, while retaining a founder veto and raising questions about valuation, liquidity and scalability.
Head of China’s “Universe” Law Firm Surrenders as Tens of Billions‑Yuan Financing Shock Unnerves Investors
Yingke, the world’s largest law firm by lawyers, faces a reputational and legal crisis after financing guarantees tied to its former global chair, Mei Xiangrong, collapsed. Investigations are under way in Shanghai amid reports that investors — many elderly — were sold high‑yield contracts leveraging the firm’s brand, and Mei has turned himself in to police.
He Gave Away the Crown: Yu Donglai Turns Nearly ¥4bn into Employee Ownership to Lock in Stability
Yu Donglai has converted about ¥3.8 billion of his retail chain’s assets into employee share capital, granting staff equity, dividend rights and profit‑linked bonuses while retaining a one‑vote veto as an adviser. The plan embeds a decision committee dominated by grassroots representatives and aims to preserve stability, align incentives and avoid a public listing. Observers see the move as a defensive, governance‑driven response to succession, social expectations on wealth distribution and a shifting regulatory environment.
China CRO ‘Hoards Monkeys, Sells Shares’: Major Holders Exit as Zhaoyan’s Earnings Mask Weak Core Business
Zhaoyan New Drug saw its shares tumble after major shareholders announced plans to sell their entire holdings, triggering a market rout. The company’s improved 2025 net profit projection is driven largely by non‑cash fair‑value gains on biological assets, while its core CRO business faces revenue decline and negative operating profit amid sector overcapacity and price competition.
A Founder’s Last Bet: How Pangdonglai Tied Employees’ Wealth to a Risky Mega‑Mall
Pangdonglai founder Yu Donglai has converted nearly RMB 3.8 billion of internal profit‑sharing allocations into recorded “asset shares” tied to a new RMB 6.5 billion Dream City development. The allocations are book entries granting future profit‑sharing rights, not tradable equity, leaving employees dependent on the company’s governance and the success of a single, large project.
From Advertising Triumph to Boardroom Crisis: China’s Kuihua, the Once‑Untouchable Children’s Drug Champion, Stumbles
Kuihua Pharmaceutical, a once‑dominant Chinese maker of children’s OTC medicines famous for its ‘Little Sunflower’ parenting programme, has reported its first annual loss since listing and seen a wave of senior departures. The collapse highlights the fragility of marketing‑led OTC business models, concentrated customer exposure and governance risks in family‑run firms following an earlier criminal scandal involving the founder.
Cambrian’s Cash Gift: A Timely Dividend That Quietly Clears a Regulatory Hurdle
Cambrian reported its first annual profit in 2025 and proposed its first cash dividend of about RMB632 million. However, the payout followed a parent‑level accounting adjustment using capital reserves that created distributable profits and positioned the dividend just above a regulatory 30% threshold, clearing the way for possible controlling‑shareholder sell‑downs while the company still faces sizeable cash‑flow and funding gaps.
State‑TV ‘3·15’ Exposé Names Duofuduo Subsidiary in Bleached‑Chicken‑Feet Scandal, Raising Governance and Regulatory Risks
CCTV’s consumer‑rights programme named Henan Yifeng, a 54%‑owned subsidiary of listed chemical firm Duofuduo, in an exposé on hydrogen peroxide being used to bleach chicken feet. Duofuduo says Yifeng is properly licensed, accounts for under 1% of group revenue and has no business ties to the processors named, but the related‑party acquisition and state‑TV attention raise governance, reputational and regulatory risks.
Moutai’s Money Manager Falls: Probe of CFO-Board Secretary Exposes Governance Risks at China’s Most Valuable Liquor Firm
Guizhou provincial investigators have placed Kweichow Moutai’s chief financial officer and company secretary Jiang Yan under disciplinary and criminal scrutiny. Her role overseeing Moutai’s finance arms and capital operations makes the inquiry significant for corporate governance and investor confidence in one of China’s most valuable listed companies.
Another Maotai Executive Falls: What Repeated Corruption at China’s National Liquor Giant Reveals
Kweichow Moutai’s finance chief Jiang Yan is under disciplinary investigation, the latest in a string of probes that have ensnared successive top executives at the company. The pattern exposes deep governance challenges tied to Moutai’s quota-driven, high-value market and signals continued central and provincial scrutiny of state-linked corporate elites.
Moutai’s Finance Chief Placed Under Liuzhi in Supervisory Probe, Exposing Governance Risks
Kweichow Moutai announced that its vice‑general manager, CFO and board secretary, Jiang Yan, has been placed under liuzhi by the Zunyi Municipal Supervisory Commission. The move highlights governance and reputational risk at one of China’s flagship state‑linked consumer companies and could spur further regulatory scrutiny.